Study the Safety and Efficacy of Probiotics Use in Premature Infants
Overview
Prophylactic enteral probiotics may enhance clinical markers and biomarkers of preterm infants' health, and may also play a role in reducing NEC and associated morbidity.
Study Type
- Study Type: Interventional
- Study Design
- Intervention Model: Parallel Assignment
- Study Primary Completion Date: December 2016
Interventions
- Dietary Supplement: breast milk with Bifidobacterium Longum subp. Infantis R0033
- Dietary Supplement: breast milk
Clinical Trial Outcome Measures
Primary Measures
- Calprotectin will be used to determine the effect for probiotics
- Time Frame: day1 and day30 of the observation
Participating in This Clinical Trial
Inclusion Criteria
- born with weight<1500 g – hospitalized within 48 hours after birth Exclusion Criteria:
- present with evidence or suspicion of congenital intestinal obstruction – perforation – gastroschisis – large omphalocele – congenital diaphragmatic hernia – major congenital heart defects
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 2 Days
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- University of Manitoba
- Collaborator
- Lallemand Health Solutions
- Provider of Information About this Clinical Study
- Principal Investigator: Dr. James Friel, Professor – University of Manitoba
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.